ACUTE ISCHAEMIC STROKE

โœ“ Medically ReviewedNEUROLOGYID: MDBTH006ICD-11: BA80๐Ÿšจ CRITICAL PROTOCOL
๐Ÿ’ก Core Clinical Guidance

Acute ischaemic stroke is a sudden-onset neurological deficit caused by focal cerebral, spinal, or retinal infarction due to arterial occlusion or severe hypoperfusion. It is diagnosed clinically and confirmed by neuroimaging demonstrating a corresponding area of infarction. Ischaemic stroke accounts for approximately 85% of all strokes.

๐Ÿ“–

Definition

CLINICAL DEFINITION & PATHOPHYSIOLOGY

Acute ischaemic stroke is a sudden-onset neurological deficit caused by focal cerebral, spinal, or retinal infarction due to arterial occlusion or severe hypoperfusion. It is diagnosed clinically and confirmed by neuroimaging demonstrating a corresponding area of infarction. Ischaemic stroke accounts for approximately 85% of all strokes.

๐Ÿ’Š

Pharmacological Management โ˜…

FIRST-LINE REGIMENS

๐Ÿ’Š Alteplase (IV thrombolysis)

PREFERRED
0.9 mg/kg (max 90 mg); 10% as IV bolus, remainder over 60 minutesIVSingle doseSingle infusion

Time window: within 4.5 hours of symptom onset; requires exclusion of haemorrhage by CT. Can be extended up to 9 hours with perfusion imaging (MRI/CT)

๐Ÿ’Š Tenecteplase

0.25 mg/kg (max 25 mg)IVSingle IV bolusSingle dose

Alternative to alteplase; non-inferior in trials; simpler administration (single bolus)

ALTERNATIVE & ESCALATION REGIMENS

๐Ÿ’Š Aspirin 300 mg

300 mgPO or NGOnce daily2 weeks (acute phase), then switch to long-term antiplatelet

Start 24 hours after thrombolysis; start immediately if thrombolysis not given. Reduces risk of early recurrence by 13%

ADJUNCTIVE & ADD-ON THERAPIES

๐Ÿ’Š Mechanical thrombectomy (endovascular clot retrieval): for LVO within 6โ€“24 hours (with salvageable penumbra on perfusion imaging)

๐Ÿ’Š Dual antiplatelet (aspirin + clopidogrel) for 21 days in minor stroke or high-risk TIA (POINT and CHANCE trials)

๐Ÿ’Š Anticoagulation for AF-related stroke: start after 2โ€“14 days depending on stroke size (DOAC preferred: apixaban or rivaroxaban)

๐Ÿ’Š Statin (atorvastatin 40โ€“80 mg) initiated acutely; continued lifelong for secondary prevention

๐Ÿ’Š Antihypertensive therapy: initiate at 24โ€“48 hours (not acutely unless severe hypertension)

๐Ÿ’Š Carotid endarterectomy or stenting within 2 weeks for symptomatic carotid stenosis โ‰ฅ50%

SPECIAL PATIENT POPULATIONS
PREGNANCY
  • Alteplase can be considered in severe stroke; limited evidence
  • Mechanical thrombectomy preferred if LVO
  • LMWH for anticoagulation
GERIATRICS
  • Thrombolysis benefit extends to elderly (>80 years) with careful selection
  • Higher bleeding risk
  • Comprehensive geriatric assessment post-stroke for rehabilitation
PAEDIATRICS
  • Rare; investigate for cardiac, haematological, metabolic causes
  • Aspirin for secondary prevention (avoid in <16 years for Reye syndrome risk, but used under specialist guidance in stroke)
RENAL IMPAIRMENT
  • Adjust antihypertensive agents
  • DOACs: use with caution; apixaban preferred in moderate CKD
HEPATIC IMPAIRMENT
  • Avoid DOACs in severe hepatic impairment
  • Statins with caution
CONTRAINDICATIONS & SAFETY CAUTIONS
  • Thrombolysis absolute contraindications: haemorrhage on CT, SBP >185 despite treatment, recent major surgery, intracranial neoplasm, active bleeding, oral anticoagulant use with INR >1.7 or DOAC within 48 hours, blood glucose <2.7 or >22 mmol/L
  • Do not lower blood pressure acutely unless >220/120 (without thrombolysis) or >185/110 (before thrombolysis)
  • Aspirin: avoid for 24 hours after thrombolysis
  • Anticoagulation: avoid in large infarcts due to haemorrhagic transformation risk
โš–๏ธCLINICAL NOTICE & EDUCATIONAL DISCLAIMER

All content in Medobo is for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional and local institutional protocols before administering medication or initiating treatment.